Samuel Álvarez-Arguedas is doing his PhD in Biochemistry and Molecular Biology at the University of Zaragoza, Spain, under the supervision of Prof. Carlos Martín, focusing on the study and characterization of the new tuberculosis vaccine, MTBVAC. Focused in the effect of MTBVAC on immunotherapy of bladder cancer cells and the study of the transcriptoma in vivo of Mycobacterium tuberculosis, he is doing an internship in the group of Roland Brosch to study the rol of the PE/PPE proteins in MTBVAC. He is interested in knowing the contribution to the immunogenicity and localization of the PE/PPE proteins of ESX-1 and ESX-5 locus.
Colorized scanning electron micrograph of Mycobacterium tuberculosis
Member: PhD Student